Regeneron Pharmaceuticals (REGN) Stock Forecast & Price Target

Regeneron Pharmaceuticals is poised for significant growth with revised US peak sales estimates for Dupixent reaching approximately $21 billion by 2030, driven by expansion into additional indications and strong physician overlap. The profitability from the Sanofi collaboration is expected to enhance margins as the development balance is repaid by the third quarter of 2026, with collaboration revenue projected to increase by $1 billion in 2027. Furthermore, the company's diverse pipeline, including advancements in oncology, neurology, and successful allergy programs, positions Regeneron for continued performance and revenue growth beyond its core products.

Regeneron Pharmaceuticals faces a negative outlook primarily due to declining sales of EYLEA, attributed to increasing competition from biosimilars and a slow transition to EYLEA HD, which threatens the company’s revenue streams. Additionally, the uncertainty surrounding the success of its development pipeline, including the potential failure of key programs like Libtayo in oncology, raises concerns about long-term revenue growth and management's capacity to execute effectively. Moreover, there exists the risk that Dupixent could underperform both domestically and internationally, further jeopardizing Regeneron's financial prospects and potentially leading to revenue and earnings per share falling below expectations.